[144] Thermo Fisher Scientific, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Thermo Fisher Scientific (TMO) shows a proposed sale of 10,000 common shares through Fidelity Brokerage Services with an aggregate market value of $5,009,587.68, and lists prior sales by the same seller during August 2025 totaling 18,496 shares for gross proceeds of $8,196,802.53. The filing states the 10,000 shares were acquired by option grant (original grant date 02/26/2019) and scheduled for sale and payment on 08/22/2025 for cash. The table lists the issuer’s outstanding shares as 377,612,121 and the planned execution on the NYSE. The filer certifies, by signing the notice, that they are not aware of undisclosed material adverse information and references Rule 10b5-1 procedures if applicable.

Positive

• Transparent disclosure of proposed sale and recent insider transactions in compliance with Rule 144
• Securities to be sold were acquired by option grant and the filing states cash payment, clarifying transaction type

Negative

• Significant insider selling in August 2025 totaling 28,496 shares (including the proposed 10,000) for gross proceeds of approximately $13.2 million
• Large dollar value of proposed sale (~$5.0 million) which may attract investor attention despite being small relative to outstanding shares

Insights

Securities Analyst

TL;DR: Insider selling disclosed; planned sale is sizable in dollar terms but small relative to outstanding shares.

The filing documents a proposed open-market sale of 10,000 common shares with an indicated market value of about $5.0 million, and shows prior August 2025 disposals by the same individual totaling 18,496 shares for roughly $8.2 million. The shares to be sold were acquired via an option grant dated 02/26/2019 and the planned sale is to occur through Fidelity on the NYSE on 08/22/2025. From an investor monitoring perspective, the filing provides transparent compliance with Rule 144 requirements and records recent insider liquidity events; the filing itself does not provide any company operational or financial data.

Corporate Governance Expert

TL;DR: The disclosure meets Rule 144 reporting requirements and documents cash settlement of exercised options.

The notice indicates the seller intends to monetize equity acquired from an option grant, with payment in cash on the indicated sale date. The form includes multiple recent sales by the same person in August 2025 and an explicit certification regarding absence of undisclosed material adverse information. This filing is procedural and related to insider liquidity; it does not state any change in company governance, control, or operational metrics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	10000	5009587.68	377612121	08/22/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2025	Option Granted - 02/26/2019	Issuer			10000	08/22/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/06/2025	10000	4518207.00
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/07/2025	8000	3635549.60
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/19/2025	201	100533.57
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/20/2025	295	147512.36

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing for Thermo Fisher Scientific (TMO) disclose?

The filing discloses a proposed sale of 10,000 common shares via Fidelity with an aggregate market value of $5,009,587.68 and prior August 2025 sales by the same seller totaling 18,496 shares for gross proceeds of $8,196,802.53.

When are the proposed shares in the TMO Form 144 scheduled to be sold?

The notices list the approximate date of sale as 08/22/2025 and prior sales occurred on 08/06/2025, 08/07/2025, 08/19/2025 and 08/20/2025.

How were the shares being sold acquired according to the filing?

The 10,000 shares to be sold were recorded as acquired on 08/22/2025 from an option grant dated 02/26/2019, with payment by cash.

Through which broker and exchange will the TMO shares be sold?

The filing names Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI) as the broker and lists the NYSE as the exchange.

How many shares of the issuer are outstanding as reported in this Form 144?

The filing reports 377,612,121 shares outstanding.